- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Post-Conference Perspectives: Key Takeaways From Recent Psoriasis Abstracts
Aaron Farberg, MD, discusses how real-world studies like tildrakizumab’s help confirm efficacy and adherence outside trials, with multisite inclusion enhancing generalizability. Results aligned with clinical trials, highlighting better adherence. The VISIBLE study emphasized comorbidity impact, influencing clinical decisions and payer perspectives. Biosimilars’ role in clinical trials ensures safety and efficacy, with interchangeability gaining clinical adoption.
EP. 1: Real-World Insights on Tildrakizumab
March 28th 2025An expert discusses how the study assessed real-world effectiveness of tildrakizumab for moderate to severe plaque psoriasis, crucial for validating clinical trial results. Multisite data enhanced reliability, while a systematic review and meta-analysis confirmed efficacy, safety, and quality of life benefits, aligning with trial findings.
Watch
